drugset / Trial / NCT00165217
Capecitabine and Thalidomide in Previously Treated Metastatic Colorectal Carcinoma
Phase 2
Completed
37 enrolled
Dana-Farber Cancer Institute
Brigham and Women's Hospital · collabMassachusetts General Hospital · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to collect information about the antitumor activity and the safety of capecitabine and thalidomide in patients with colorectal cancer.
Timeline
- Start
- 2001-11
- Primary completion
- 2005-12
- Completion
- 2005-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | — | Oral |
| Subject | Thalidomide | Other / unclassified | 600 mg | Oral |